tbuckley/cabot-search huggingface dataset:
Undermining Value-Based Purchasing — Lessons from the Pharmaceutical Industry
Authors: Leemore S. Dafny, Christopher J. Ody, Matthew A. Schmitt
Journal: New England Journal of Medicine (2016)

Interview with Dr. Leemore Dafny on ways in which health care providers could undermine efforts to steer consumers toward high-value care. (10:05)Download Although it's not yet clear how health care providers will respond to value-based payment models, an examination of pharmaceutical industry practices can provide insights into problems that may arise — and practices to avoid.
Identification of Transcription Factor AP-1 Bound to Untranslated 5′ Regulatory Region DNA of mdr1 Gene with Atomic Force Microscopy.
Authors: Bao-An Chen, Jie Xiong, Long Ba, Feng Gao, Chong Gao, Jia-Hua Ding, Yun-Yu Sun, Jian Cheng, Jun Wang, Gang Zhao, Zu-Hong Lu, Ning-Na Chen, Fei Fei
Journal: Blood (2006)
Bortezomib and Dexamethasone as Maintenance therapy in Relapse/Refractory multiple myeloma Patients
Authors: Giulia Benevolo, Alessandra Larocca, Patrizia Pregno, Francesca Gay, Barbara Botto, Lorella Orsucci, Andrea Evangelista, Antonio Palumbo, Umberto Vitolo, Mario Boccadoro
Journal: Blood (2008)
Genomic Segmental Duplications at the Basis of t(9;22) Rearrangement in Chronic Myeloid Leukemia.
Authors: Francesco Albano, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Pietro D'Addabbo, Vincenzo Liso, Mariano Rocchi, Giorgina Specchia
Journal: Blood (2009)
Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project.
Authors: C. Zornosa, R. Mamet, M. E. Reid, D. S. Ettinger, G. A. Otterson, M. S. Rabin, J. Hayman, J. C. Niland, K. Pisters
Journal: Journal of Clinical Oncology (2010)

7017 Background: In recent years, adjuvant chemotherapy has become the standard of care for completely resected (R0) stage II and IIIA NSCLC patients, while the use of adjuvant therapy in stage IB remains controversial. We evaluated the use of adjuvant therapy among R0 stage IA-IIIA NSCLC patients in the NCCN Outcomes Database Project. Methods: Completely resected stage I-IIIA NSCLC patients who did not receive preoperative therapy were selected for analysis. Eligible patients received adjuvant treatment at 8 participating NCCN institutions between 01/2007 and 06/2009 and were at least 90 days postsurgery. Adjuvant therapy was defined as therapy initiated within 3 months of surgery. Analyses were done on 12/11/09. Results: A total of 498 patients met the inclusion criteria. Patient characteristics were: male 42%; median age 67 yrs; stage IA 39%, IB 35%, II 16%, IIIA 10%; lobectomy (uni or bi) 84% (N=416); adenocarcinoma 58% (N=289); performance status (PS) 0-1 54% (N=271), PS ≥2 3% (N=16), and undocumented PS 42% (N=211). Adjuvant treatment category is presented by stage in the Table. Of patients receiving adjuvant therapy, 5 (4%) did so on a clinical trial. The most common reason for not receiving adjuvant systemic therapy in stage II-IIIA was patient refusal (26%). Conclusions: Adjuvant therapy was commonly administered to stage II and IIIA patients. Radiation was most common among stage IIIA patients. While the majority of R0 NSCLC patients received treatment that follows NCCN guidelines, relatively few patients at these NCCN centers are participating in clinical trials. Adjuvant treatment category by stage Treatment category Stage IA (N=193) IB (N=174) II (N=79) IIIA (N=52) No treatment 190 (98%) 126 (72%) 25 (32%) 14 (27%) Chemotherapy 2 (1%) 43 (25%) 43 (54%) 20 (38%) Cisplatin-based 2 (100%) 25 (58%) 25 (58%) 10 (50%) Carboplatin-based 0 (0%) 14 (33%) 17 (40%) 8 (40%) Other 0 (0%) 4 (9%) 1 (2%) 2 (10%) Chemotherapy + targeted therapy 0 (0%) 2 (1%) 0 (0%) 0 (0%) Targeted therapy alone 0 (0%) 2 (1%) 2 (3%) 1 (2%) Sequential chemo/RT 1 (<1%) 0 (0%) 6 (8%) 13 (25%) Concurrent chemo/RT 0 (0%) 0 (0%) 1 (1%) 3 (6%) RT alone 0 (0%) 1 (<1%) 2 (3%) 1 (2%) Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Abraxis BioScience
TCT-265 Impact of Platelet Count on Myocardial Infarct Size and Adverse Events in Anterior ST-Elevation Myocardial Infarction: Results from the INFUSE-AMI Trial
Authors: Gennaro Giustino, Sorin Brener, Akiko Maehara, Roxana Mehran, Philippe Genereux, Dariusz Dudek, Thomas Neunteufl, D. Christopher Metzger, M.O. Ozan, C. Michael Gibson, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2015)
Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis
Authors: Amber Kunkel, Frank G. Cobelens, Ted Cohen
Journal: PLoS Medicine (2016)

New drugs for the treatment of tuberculosis (TB) are becoming available for the first time in over 40 y. Optimal strategies for introducing these drugs have not yet been established. The objective of this study was to compare different strategies for introducing the new TB drug bedaquiline based on patients' resistance patterns.We created a Markov decision model to follow a hypothetical cohort of multidrug-resistant (MDR) TB patients under different bedaquiline use strategies. The explored strategies included making bedaquiline available to all patients with MDR TB, restricting bedaquiline usage to patients with MDR plus additional resistance and withholding bedaquiline introduction completely. We compared these strategies according to life expectancy, risks of acquired resistance, and the expected number and health outcomes of secondary cases. For our simulated cohort, the mean (2.5th, 97.5th percentile) life expectancy from time of initiation of MDR TB treatment at age 30 was 36.0 y (33.5, 38.7) assuming all patients with MDR TB received bedaquiline, 35.1 y (34.4, 35.8) assuming patients with pre-extensively drug-resistant (PreXDR) and extensively drug-resistant (XDR) TB received bedaquiline, and 34.9 y (34.6, 35.2) assuming only patients with XDR TB received bedaquiline. Although providing bedaquiline to all MDR patients resulted in the highest life expectancy for our initial cohort averaged across all parameter sets, for parameter sets in which bedaquiline conferred high risks of added mortality and only small reductions in median time to culture conversion, the optimal strategy would be to withhold use even from patients with the most extensive resistance. Across all parameter sets, the most liberal bedaquiline use strategies consistently increased the risk of bedaquiline resistance but decreased the risk of resistance to other MDR drugs. In almost all cases, more liberal bedaquiline use strategies reduced the expected number of secondary cases and resulting life years lost. The generalizability of our results is limited by the lack of available data about drug effects among individuals with HIV co-infection, drug interactions, and other sources of heterogeneity, as well as changing recommendations for MDR TB treatment.If mortality benefits can be empirically verified, our results provide support for expanding bedaquiline access to all patients with MDR TB. Such expansion could improve patients' health, protect background MDR TB drugs, and decrease transmission, but would likely result in greater resistance to bedaquiline.
TCT-569 Biodegradable-polymer-based, argatroban-eluting, cobalt chromium stent (JF-04) for treatment of native coronary lesions: Final results of the first-in-man study in Japan
Authors: Yoshihiro Morino, Tetsuya Tobaru, Satoshi Yasuda, Kazuaki Kataoka, Kengo Tanabe, Atsushi Hirohata, Ken Kozuma, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2015)
Efficacy and Safety of Outpatient Treatment Based on the Hestia Clinical Decision Rule with or without N-Terminal Pro–Brain Natriuretic Peptide Testing in Patients with Acute Pulmonary Embolism. A Randomized Clinical Trial
Authors: Paul L. den Exter, Wendy Zondag, Frederikus A. Klok, Rolf E. Brouwer, Janneke Dolsma, Michiel Eijsvogel, Laura M. Faber, Marijke van Gerwen, Marco J. Grootenboers, Roxane Heller-Baan, Marcel M. Hovens, Gé J. P. M. Jonkers, Klaas W. van Kralingen, Christian F. Melissant, Henny Peltenburg, Judith P. Post, Marcel A. van de Ree, L. Th. (Tom) Vlasveld, Mariëlle J. de Vreede, Menno V. Huisman
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Outpatient treatment of pulmonary embolism (PE) may lead to improved patient satisfaction and reduced healthcare costs. However, trials to assess its safety and the optimal method for patient selection are scarce.To validate the utility and safety of selecting patients with PE for outpatient treatment by the Hestia criteria and to compare the safety of the Hestia criteria alone with the Hestia criteria combined with N-terminal pro-brain natriuretic peptide (NT-proBNP) testing.We performed a randomized noninferiority trial in 17 Dutch hospitals. We randomized patients with PE without any of the Hestia criteria to direct discharge or additional NT-proBNP testing. We discharged the latter patients as well if NT-proBNP did not exceed 500 ng/L or admitted them if NT-proBNP was greater than 500 ng/L. The primary endpoint was 30-day adverse outcome defined as PE- or bleeding-related mortality, cardiopulmonary resuscitation, or intensive care unit admission. The noninferiority margin for the primary endpoint was 3.4%.We randomized 550 patients. In the NT-proBNP group, 34 of 275 (12%) had elevated NT-proBNP values and were managed as inpatients. No patient (0 of 34) with an elevated NT-proBNP level treated in hospital (0%; 95% confidence interval [CI], 0-10.2%), versus no patient (0 of 23) with a post hoc-determined elevated NT-proBNP level from the direct discharge group (0%; 95% CI, 0-14.8%), experienced the primary endpoint. In both trial cohorts, the primary endpoint occurred in none of the 275 patients (0%; 95% CI, 0-1.3%) subjected to NT-proBNP testing, versus in 3 of 275 patients (1.1%; 95% CI, 0.2-3.2%) in the direct discharge group (P = 0.25). During the 3-month follow-up, recurrent venous thromboembolism occurred in two patients (0.73%; 95% CI, 0.1-2.6%) in the NT-proBNP group versus three patients (1.1%; 95% CI, 0.2-3.2%) in the direct discharge group (P = 0.65).Outpatient treatment of patients with PE selected on the basis of the Hestia criteria alone was associated with a low risk of adverse events. Given the low number of patients with elevated NT-proBNP levels, this trial was unable to draw definite conclusions regarding the incremental value of NT-proBNP testing in patients who fulfill the Hestia criteria. Clinical trial registered with www.trialregister.nl/trialreg/admin/rctview.asp?TC=2603 (NTR2603).
CELL INTERACTIONS BETWEEN HISTOINCOMPATIBLE T AND B LYMPHOCYTES
Authors: David H. Katz, Toshiyuki Hamaoka, Baruj Benacerraf
Journal: The Journal of Experimental Medicine (1973)

Several experimental approaches, designed specifically to circumvent the possible contribution of a complicating "allogeneic effect," have been successfully used to answer the question of physiologic cooperative interactions between histoincompatible T and B lymphocytes in antibody responses to hapten-protein conjugates. This was accomplished for in vivo cell transfer studies by using an F(1) hybrid host as the recipient of irradiated, carrier-primed T lymphocytes from one parent and 2,4-dinitrophenyl (DNP)-primed B lymphocytes from the opposite strain. Under these conditions, very good T-B cell cooperative interactions were observed to occur between T and B lymphocyte populations derived from syngeneic donors, whereas no cooperative response was obtained when T cells were derived from one parental strain and B cells from the other. Corroborative experiments were performed in a totally in vitro system in which DNP-primed B cells developed good secondary anti-DNP antibody responses in vitro to soluble DNP-keyhole limpet hemocyanin (KLH) when cultured in the presence of irradiated KLH-primed T cells derived from syngenic donors but not from allogeneic donors. The failure of histoincompatible T and B lymphocytes to effect physiologic cooperative interactions has important implications for our understanding of how such interactions normally occur. The possibility that these results reflect the existence of a "block" of some sort to cell-cell interaction by virtue of the presence of a foreign major histocompatibility antigen on the surface of either cell has been definitively ruled out in the present studies. These observations demonstrate that the gene(s) that conditions the capability for physiologic T-B cell cooperation must be shared in common by the respective cell types, and suggest, furthermore, that this gene (or genes) belongs to the major histocompatibility system of the mouse. These findings, together with other relevant phenomena described previously, have led us to postulate that there exists on the B lymphocyte surface an "acceptor" molecule either for the putative active T cell product or for the T cell itself. The important genetic considerations and the possible sequence of events surrounding the actual T-B cell interaction implied by these postulates are discussed in detail.
Risk Factors Affecting Outcome of Transplantation in Pediatric Acute Lymphoblastic Leukemia: Results of the International BFM ALL SCT Study
Authors: Adriana Balduzzi, Jean-Hugues Dalle, Arjan C Lankester, Isaac Yaniv, Akif Yesilipek, Petr Sedlacek, Marianne Ifversen, Sabina Sufliarska, Marc B Bierings, Jacek Wachowiak, Jacek Toporski, Ulrike Poetschger, Evgenia Glogova, Ingeborg Hirsch, Christina Peters
Journal: Blood (2015)
Escitalopram and Outcomes Among Patients With Depression and Heart Failure—Reply
Authors: Christiane E. Angermann, Jürgen Deckert, Georg Ertl
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Does efficacy of non-estrogenic therapies for hot flashes among women vary by breast cancer history and tamoxifen use? A pooled analysis
Authors: A. Bardia, P. J. Novotny, J. A. Sloan, D. L. Barton, P. D. Steen, C. Watson, B. Christensen, C. L. Loprinzi
Journal: Journal of Clinical Oncology (2008)

9595 Background: Various non-estrogenic therapies have been found to be effective in mitigating hot flashes. However, it is unclear whether the efficacy of these therapies is different among women with breast cancer, and/or those taking tamoxifen, as compared to the counterparts. Methods: All clinical trials (pilot and randomized trials) conducted by a group of investigators at Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) that evaluated the efficacy of any non-estrogenic agent for hot flashes, and had information on breast cancer history and/or tamoxifen use, were eligible for this analysis. All these trials had similar study methodology, including design and measurement tools. Hot flash scores were computed as the daily frequency of hot flashes times the average hot flash severity. The analysis was done using patient level data. Statistically significant changes from the 4th treatment week versus the baseline week were assessed using the Student’s t-test. Forest plots as well as stepwise linear regression models were created to assess the differences among subgroups. A p-value of 0.05 was considered significant. Results: A total of 1,415 women from 20 hot flash studies were eligible for analysis. Among the patients with available information, 80% had a history of breast cancer and 53% were using tamoxifen. Overall, patients without breast cancer had similar percentage of baseline hot flash score at week four, as did those with breast cancer (53% versus 50%, p=0.92). Patients without a history of tamoxifen use had a significantly lower percentage of hot flash score at week four, as compared to those who used tamoxifen (54% versus 61%, p =0.01). However, further analysis showed that this was due to a higher reduction of hot flashes in the placebo arms among patients not receiving tamoxifen. The percentage reduction in hot flash score at week 4 (from baseline) by the therapy arms over placebo arms in the randomized trials, and by the therapies in pilot trials, was similar among tamoxifen users and non- users. Conclusions: The efficacy of non-estrogenic therapies on hot flashes is similar among women with or without a history of breast cancer, as well as among patients taking tamoxifen versus non-users. No significant financial relationships to disclose.
Comparison of Autologous Vs. Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma
Authors: Nishitha M. Reddy, Olalekan O Oluwole, John P Greer, David S Morgan, Stacey Goodman, Brian Engelhardt, Wichai Chinratanalab, Adetola A Kassim, Madan Jagasia, Bipin N. Savani
Journal: Blood (2012)
<i>The Effect</i>
Authors: Abigail Zuger
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Escitalopram and Outcomes Among Patients With Depression and Heart Failure
Authors: Andreas Ströhle, Nina Rieckmann
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Announcing the New JAMADermatology.com
Authors: Paul Gee, Colleen Kelly, Michael Berkwits
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
TCT-522 Impact of Strut Distribtuion on Neointimal Coverage of Everolimus-Eluting Bioresorbable Scaffolds: An Optical Coherence Tomography Study
Authors: Takao Sato, Ralph Toelg, Mohamed El-Mawardy, Gert Richardt, Mohamed Abdel-Wahab
Journal: Journal of the American College of Cardiology (2015)